Stock Market Watch

Three NASDAQ Stocks having a Pullback: FTWR, GALE, and TNCC

by ·




FiberTower Corporation (NASDAQ:FTWR) is currently trading at the low of the day at $.26 for a loss of 10.38% from yesterday’s close. FTWR shares traded as high as $.40 so far during today’s trading session – still up nicely from its $.15 low on Friday and still up nearly 24% from my 12.5 Alert. Get my next Alert 100% FREE!

FiberTower is a backhaul and access services provider focused primarily on the wireless carrier market. With its extensive spectrum footprint in 24 GHz and 39 GHz bands, carrier-class fiber and microwave networks in 13 major markets and master service agreements with nine U.S. wireless carriers, FiberTower is an alternative carrier for wireless backhaul. FiberTower also provides backhaul and access service to government and enterprise markets. For more information, please visit our website at www.fibertower.com.

Galena Biopharma Inc (NASDAQ:GALE) has traded as high as $.72 during today’s trading session and last traded at $.52 for a 24.39% loss from yesterday’s close. GALE’s stock has so far bounced off its recent support of $.495 and will be interesting to see if it can hold above that point over the next couple days.


GALE is a Portland, Oregon-based biopharmaceutical company that develops innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. For more information please visit us at www.galenabiopharma.com. The company’s flagship drug NeuVax consists of the E75 peptide derived from human epidermal growth factor receptor 2 (HER2) combined with the immune adjuvant granulocyte macrophage colony-stimulating factor (GM-CSF).

Treatment with NeuVax stimulates cytotoxic (CD8+) T cells in a highly specific manner to target cells expressing any level of HER2. NeuVax is given as an intradermal injection once a month for six months, followed by a booster injection once every six months. Based on a successful Phase 2 trial, which achieved its primary endpoint of disease free survival (DFS), the  Food and Drug Administration granted NeuVax a Special Protocol Assessment (SPA) for its Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) study. The Phase 3 trial is expected to commence in the first half of 2012.

Tennessee Commerce Bancorp, Inc. (NASDAQ:TNCC) has traded as high as $.24 during today’s trading session and last traded at $.15 for a loss of 16.67% from yesterday’s close. TNCC shares traded as high as $30 yesterday and the day it fell through the ground in October; it traded as high as $.95!

Tennessee Commerce Bancorp, Inc. is the parent company of Tennessee Commerce Bank (the “Bank”).The Bank provides a wide range of banking services and is primarily focused on business accounts. Its corporate and banking offices are located in Franklin, Tennessee. The Company’s common stock is traded on the NASDAQ Global Market under the symbol “TNCC.”Additional information about Tennessee Commerce Bancorp, Inc. and Tennessee Commerce Bank can be accessed at www.tncommercebank.com.

 

More Posts by this author

Post Written By: Oliver Crowne

Oliver Crowne is the main editor for http://www.StockPreacher.com


Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...